{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:04:04Z","timestamp":1789967044248,"version":"4.0.1"},"reference-count":71,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:p>The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost\u2010effectiveness and inform reimbursement and access decisions. We systematically reviewed full economic evaluations of approved antiobesity medications in adults with overweight or obesity, including tirzepatide, semaglutide, liraglutide, naltrexone\/bupropion, orlistat, phentermine and phentermine\/topiramate. Ovid MEDLINE, Embase and government websites were searched for studies comparing these medications with standard care or with each other. Methodological quality was assessed using the BMJ checklist and reporting quality using CHEERS 2022. A narrative synthesis was performed, focusing on quality\u2010adjusted life years and incremental cost\u2010effectiveness ratios. The review followed PRISMA guidelines and was registered on PROSPERO (CRD420251139475). Twenty\u2010six studies met inclusion criteria. All were conducted in high or upper\u2010middle\u2010income countries, predominantly from payer perspectives. Results were heterogeneous and sensitive to model assumptions; however, consistent trends emerged. Semaglutide demonstrated variable cost\u2010effectiveness but consistently outperformed liraglutide, which was generally not cost\u2010effective. Tirzepatide produced greater health gains and frequently favourable ICERs, though it often exceeded willingness\u2010to\u2010pay (WTP) thresholds in lower\u2010threshold settings. Among older agents, phentermine\/topiramate appeared economically competitive, largely due to lower acquisition costs. The cost\u2010effectiveness of antiobesity medications is highly context\u2010dependent. Semaglutide is generally more cost\u2010effective than liraglutide, while tirzepatide offers greater clinical benefit but may exceed WTP thresholds. Direct comparative economic evidence between newer agents remains limited. Long\u2010term real\u2010world data and clearer distinctions between cost\u2010effectiveness and affordability are needed to inform policy decisions.<\/jats:p>","DOI":"10.1002\/bcp.70825","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:16:13Z","timestamp":1789964173000},"source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluations of antiobesity medications: A systematic literature review"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8257-197X","authenticated-orcid":false,"given":"Martina","family":"Jurkovi\u0107","sequence":"first","affiliation":[{"name":"Clinical Hospital Centre Rijeka  Rijeka Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-9701","authenticated-orcid":false,"given":"Almir","family":"Fajki\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Medicine University of Sarajevo  Sarajevo Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9039-0197","authenticated-orcid":false,"given":"Andrea Katrin","family":"Faour","sequence":"additional","affiliation":[{"name":"Independent Researcher  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1871-2827","authenticated-orcid":false,"given":"Mirna","family":"Mom\u010dilovi\u0107","sequence":"additional","affiliation":[{"name":"University of Zagreb Faculty of Pharmacy and Biochemistry  Zagreb Croatia"},{"name":"University Hospital Centre Zagreb  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-8257","authenticated-orcid":false,"given":"Petra","family":"Tur\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacology University of Zagreb Faculty of Pharmacy and Biochemistry  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-6600","authenticated-orcid":false,"given":"Andrej","family":"Belan\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine University of Rijeka  Rijeka Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2019.110615"},{"key":"e_1_2_9_3_1","unstructured":"World Obesity Federation World Obesity Atlas 2025 retrieved March 26 2026 https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2025"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)00355\u20101"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae508"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003765\u2010w"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2015.59"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12551"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S008"},{"key":"e_1_2_9_10_1","unstructured":"Adult clinical practice guideline Obesity Canada retrieved November 11 2025 https:\/\/obesitycanada.ca\/healthcare-professionals\/adult-clinical-practice-guideline\/"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010026\u201004397\u20104"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003978\u2010z"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201002026\u20104"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403664"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13358"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010023\u201001398\u2010y"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1537181"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010014\u20100230\u20102"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010024\u201001473\u2010y"},{"key":"e_1_2_9_28_1","unstructured":"PRISMA statement PRISMA statement retrieved February 23 2026 https:\/\/www.prisma-statement.org"},{"key":"e_1_2_9_29_1","unstructured":"PROSPERO retrieved February 23 2026 https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251139475"},{"key":"e_1_2_9_30_1","unstructured":"QUALITY ASSESSMENT USING BMJ CHECKLIST In: Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: Review of Canadian Economic Studies Canadian Agency for Drugs and Technologies in Health;2011 retrieved February 23 2026 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK361772\/"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_2_9_32_1","unstructured":"Covidence systematic review software Veritas Health Innovation Melbourne Australia 2025 retrieved February 23 2026 https:\/\/www.covidence.org\/"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010020\u201001536\u2010x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.07.024"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.5.441"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16627"},{"key":"e_1_2_9_37_1","unstructured":"National Institute for Health and Care Excellence (NICE).Tirzepatide for managing overweight and obesity (TA1026)NICE2025. Accessed February 18 2026.https:\/\/www.nice.org.uk\/guidance\/ta1026"},{"key":"e_1_2_9_38_1","unstructured":"National Centre for Pharmacoeconomics (NCPE) Naltrexone\/bupropion (Mysimba\u00ae) for the management of weight in adults retrieved February 17 2026 https:\/\/www.ncpe.ie\/wp-content\/uploads\/2017\/03\/Mysimba-summary.pdf"},{"key":"e_1_2_9_39_1","unstructured":"National Institute for Health and Care Excellence (NICE) Naltrexone\u2013bupropion for managing overweight and obesity (TA494) retrieved February 17 2026 https:\/\/www.nice.org.uk\/guidance\/ta494"},{"key":"e_1_2_9_40_1","unstructured":"Scottish Medicines Consortium (SMC) Tirzepatide solution for injection in pre\u2010filled pen (Mounjaro\u00ae) (SMC2633) 2024Glasgow SMC (updated 2025) retrieved February 18 2026 www.scottishmedicines.org.uk"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202405_36181"},{"key":"e_1_2_9_42_1","unstructured":"Semaglutide (Wegovy): CADTH Reimbursement Recommendation Canadian Agency for Drugs and Technologies in Health 2022 1\u201017 retrieved February 18 2026 https:\/\/www.cda\u2010amc.ca\/sites\/default\/files\/DRR\/2022\/SR0725%20Wegovy%20\u2010%20CADTH%20Final%20Recommendation\u2010meta.pdf"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16581"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2023.03.012"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.70160"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm\u201022\u2010200"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5586"},{"key":"e_1_2_9_48_1","unstructured":"AtlasSJKimKBeinfeldMet alMedications for obesity management: effectiveness and value. Final evidence report Boston Institute for Clinical and Economic Review 2022 https:\/\/icer.org\/wp-content\/uploads\/2022\/03\/ICER_Obesity_Final_Evidence_Report_and_Meeting_Summary_122223.pdf"},{"key":"e_1_2_9_49_1","unstructured":"LinGALeeWFahimSMet alSemaglutide and tirzepatide for obesity: effectiveness and value; draft evidence report Institute for Clinical and Economic Review 2025 retrieved February 18 https:\/\/icer.org\/wpcontent\/uploads\/2025\/09\/ICER_Obesity_Draft\u2010Report_For\u2010Publication_090925.pdf"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.7.740"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.390"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2459529"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098\u2010024\u201001338\u20104"},{"key":"e_1_2_9_54_1","unstructured":"Semaglutide for managing overweight and obesity NICE guidance.2023 retrieved February 18 2026 https:\/\/www.nice.org.uk\/guidance\/ta875\/resources\/semaglutide\u2010for\u2010managing\u2010overweight\u2010and\u2010obesity\u2010pdf\u201082613674831813"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010024\u201001467\u2010w"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2024.09.025"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002423\u20108"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102023\u2010330437"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcae063"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12294"},{"key":"e_1_2_9_61_1","unstructured":"Cost\u2010effectiveness of liraglutide 3mg (Saxenda\u00ae) as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with a body mass index of \u226535kg\/m2 with pre\u2010diabetes and high risk of cardiovascular disease retrieved February 18 2026 https:\/\/ncpe.ie\/wp\u2010content\/uploads\/2021\/02\/Summary\u2010Liraglutide\u2010weight\u2010management\u2010Saxenda\u201009\u201002\u20102021\u20101.pdf"},{"key":"e_1_2_9_62_1","unstructured":"Liraglutide for managing overweight and obesity NICE guidance2020 retrieved February 18 2026 https:\/\/www.nice.org.uk\/guidance\/ta664\/resources\/liraglutide\u2010for\u2010managing\u2010overweight\u2010and\u2010obesity\u2010pdf\u201082609259121349"},{"key":"e_1_2_9_63_1","unstructured":"SMC liraglutide 6mg\/mL solution for injection in pre\u2010filled pen (Saxenda\u00ae) retrieved February 18 2026 https:\/\/scottishmedicines.org.uk\/media\/6360\/liraglutide\u2010saxenda\u2010final\u2010sept\u20102021\u2010amended\u2010081021\u2010for\u2010website.pdf"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010025\u201003288\u20103"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24310"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16466"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010024\u201003755\u2010w"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010021\u201001053\u20107"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467\u2010789X.2005.00211.x"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802947"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S528064"},{"key":"e_1_2_9_72_1","unstructured":"European Association for the Study of Diabetes Most quit breakthrough weight\u2010loss drug within a year 2025 ScienceDaily ScienceDaily retrieved February 18 2026 https:\/\/www.sciencedaily.com\/releases\/2025\/09\/250913232157.htm"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70825","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:16:22Z","timestamp":1789964182000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":71,"alternative-id":["10.1002\/bcp.70825"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70825","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"article-number":"bcp.70825"}}